Description of Treatment Patterns and Description and Comparison of Healthcare Resource Utilization and Costs of Women With Metastatic HR+/HER2- Breast Cancer Treated With CDK4/6 Inhibitors
Status: COMPLETED
Study type: OBSERVATIONAL
Conditions: Metastatic Breast Cancer
Interventions: DRUG: Ribociclib|DRUG: Palbociclib|DRUG: Abemaciclib
Sponsor: Novartis Pharmaceuticals